Cargando…

In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis

Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its efficacy against Leishmania donovani has been well documented. Leishmania amazonensis is the second most prevalent species causing cutaneous leishmaniasis and the main etiological agent of diffuse cutan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coelho, Adriano C., Trinconi, Cristiana T., Costa, Carlos H. N., Uliana, Silvia R. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102453/ https://www.ncbi.nlm.nih.gov/pubmed/25033218 http://dx.doi.org/10.1371/journal.pntd.0002999

Ejemplares similares

In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up
por: Coelho, Adriano C., et al.
Publicado: (2016)

Generation of Luciferase-Expressing Leishmania infantum chagasi and Assessment of Miltefosine Efficacy in Infected Hamsters through Bioimaging
por: Reimão, Juliana Q., et al.
Publicado: (2015)

Successful treatment of diffuse cutaneous leishmaniasis caused by Leishmania amazonensis()()
por: Sampaio, Raimunda Nonata Ribeiro, et al.
Publicado: (2021)

A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome
por: Coelho, Adriano C., et al.
Publicado: (2016)

Exposure of Phosphatidylserine on Leishmania amazonensis Isolates Is Associated with Diffuse Cutaneous Leishmaniasis and Parasite Infectivity
por: França-Costa, Jaqueline, et al.
Publicado: (2012)

Draft Genome Sequences of Leishmania (Leishmania) amazonensis, Leishmania (Leishmania) mexicana, and Leishmania (Leishmania) aethiopica, Potential Etiological Agents of Diffuse Cutaneous Leishmaniasis
por: Batra, Dhwani, et al.
Publicado: (2019)

Ros3 (Lem3p/CDC50) Gene Dosage Is Implicated in Miltefosine Susceptibility in Leishmania (Viannia) braziliensis Clinical Isolates and in Leishmania (Leishmania) major
por: Espada, Caroline R., et al.
Publicado: (2021)

Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo
por: Coser, Elizabeth M., et al.
Publicado: (2020)

Leishmania is not prone to develop resistance to tamoxifen
por: Coelho, Adriano C., et al.
Publicado: (2015)

Photodynamic Vaccination of BALB/c Mice for Prophylaxis of Cutaneous Leishmaniasis Caused by Leishmania amazonensis
por: Viana, Sayonara M., et al.
Publicado: (2018)

Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled Trial
por: Machado, Paulo R., et al.
Publicado: (2010)

SUCCESSFUL TREATMENT OF MULTIFOCAL CUTANEOUS LEISHMANIASIS WITH MILTEFOSINE
por: Madke, Bhushan, et al.
Publicado: (2011)

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017)

In Vitro Susceptibility to Miltefosine of Leishmania infantum (syn. L. chagasi) Isolates from Different Geographical Areas in Brazil
por: Espada, Caroline Ricce, et al.
Publicado: (2021)

Visceral leishmaniasis caused by Leishmania (Leishmania) amazonensis associated with Hodgkin’s lymphoma
por: Porto, Victor Bertolo Gomes, et al.
Publicado: (2022)

In Vitro and In Vivo Activity of a Palladacycle Complex on Leishmania (Leishmania) amazonensis
por: Paladi, Carolina de Siqueira, et al.
Publicado: (2012)

Induction of Early Autophagic Process on Leishmania amazonensis by Synergistic Effect of Miltefosine and Innovative Semi-synthetic Thiosemicarbazone
por: Scariot, Débora B., et al.
Publicado: (2017)

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis
por: Bhandari, Vasundhra, et al.
Publicado: (2012)

Host and parasite responses in human diffuse cutaneous leishmaniasis caused by L. amazonensis
por: Christensen, Stephen M., et al.
Publicado: (2019)

Efficacy of topical risedronate and risedronate - Eudragit E complex in a model of cutaneous leishmaniasis induced by Leishmania (Leishmania) amazonensis
por: Peralta, Ma. Florencia, et al.
Publicado: (2021)

Complex cutaneous infection by Leishmania mexicana treated with miltefosine
por: Sadowsky, Rachel L., et al.
Publicado: (2022)

DC-SIGN receptor is expressed by cells from cutaneous leishmaniasis lesions and differentially binds to Leishmania (Viannia) braziliensis and L. (Leishmania) amazonensis promastigotes
por: Mendes-Aguiar, Carolina de O, et al.
Publicado: (2023)

Tamoxifen Is Effective in the Treatment of Leishmania amazonensis Infections in Mice
por: Miguel, Danilo C., et al.
Publicado: (2008)

A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis
por: Carnielli, Juliana B.T., et al.
Publicado: (2018)

The Effect of Ursolic Acid on Leishmania (Leishmania) amazonensis Is Related to Programed Cell Death and Presents Therapeutic Potential in Experimental Cutaneous Leishmaniasis
por: Yamamoto, Eduardo S., et al.
Publicado: (2015)

Experimental transmission of Leishmania (Leishmania) amazonensis to immunosuppressed mice through the bite of Lutzomyia longipalpis (Diptera: Psychodidae) results in cutaneous leishmaniasis
por: da Silva, Rosa Cristina Ribeiro, et al.
Publicado: (2021)

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil
por: dos Santos Nogueira, Fabio, et al.
Publicado: (2019)

In Vitro Drug Susceptibility of a Leishmania (Leishmania) infantum Isolate from a Visceral Leishmaniasis Pediatric Patient after Multiple Relapses
por: Ferreira, Bianca A., et al.
Publicado: (2023)

Natural Resistance of Leishmania infantum to Miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil
por: Carnielli, Juliana B. T., et al.
Publicado: (2019)

Use of In Vivo and In Vitro Systems to Select Leishmania amazonensis Expressing Green Fluorescent Protein
por: Costa, Solange dos Santos, et al.
Publicado: (2011)

Miltefosine for the treatment of cutaneous leishmaniasis—A pilot study from Ethiopia
por: van Henten, Saskia, et al.
Publicado: (2021)

Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis
por: Giudice, Angela, et al.
Publicado: (2007)

Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis
por: Melcon-Fernandez, Estela, et al.
Publicado: (2023)

Miltefosine-Lopinavir Combination Therapy Against Leishmania infantum Infection: In vitro and in vivo Approaches
por: Rebello, Karina M., et al.
Publicado: (2019)

Sphingolipid Degradation in Leishmania (Leishmania) amazonensis
por: Pillai, Agiesh Balakrishna, et al.
Publicado: (2012)

Leishmania Exosomes/Extracellular Vesicles Containing GP63 Are Essential for Enhance Cutaneous Leishmaniasis Development Upon Co-Inoculation of Leishmania amazonensis and Its Exosomes
por: da Silva Lira Filho, Alonso, et al.
Publicado: (2022)

3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
por: Carnielli, Juliana B.T., et al.
Publicado: (2022)

1662. Pushing the Dose: Miltefosine Treatment for a Supersized American with Cutaneous Leishmaniasis
por: Aronson, Naomi E, et al.
Publicado: (2019)

Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients
por: OLLECH, Ayelet, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fhegs12h2hjeb26t9jnlae8ac9